Cancer remains the dominant disease target for biotech through to 2010
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cancer remains the dominant disease target for biotech through to 2010
Go to paperABSTRACT: The two leading therapeutic areas for biological products, in t…